The company has a team of experienced industry professionals, scientists, clinicians, and key opinion leaders from leading institutions worldwide. Biophytis is developing two proprietary drug candidates, Sarconeos (BIO101) and Macuneos (BIO201), to treat sarcopenic obesity and dry age-related macular degeneration (AMD), respectively. Their business model involves conducting the project until clinical activity is proven, then licensing the technologies to continue development in partnership with a pharmaceutical laboratory. Biophytis was founded in collaboration with researchers at the UPMC and collaborates with scientists at the Institute of Myology and the Vision Institute.